North America dominated the viral vector & plasmid DNA manufacturing market with a revenue share in 2024. Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.

The Viral Vector and Plasmid DNA Manufacturing Market refers to the industrial processes and services that enable the production of viral vectors and plasmid DNA used in gene therapies, vaccine ...

New results have highlighted the advantages of minicircles over plasmids as they avoid unnecessary bacterial backbone sequences due to higher transfection efficiencies and offer benefits especially in ...

The global viral vector & plasmid DNA manufacturing market size is expected to reach USD 882.9 million by 2025, according to a new report by Grand View Research, Inc., rising at a 16.0% CAGR during ...

The genetic medicine revolution is underway. Just 18 months ago, very few people in the general population had heard of mRNA vaccines; now, hundreds of millions globally have been vaccinated with one.

The antibody is designed to target toxic forms of TDP-43 selectively, aiming to restore normal nuclear function.

DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...

Touchlight scored another $125 million to boost manufacturing as the company looks to become a leading synthetic DNA producer for genetic medicines. The cell and gene therapy space has exploded in the ...

Every dog has its day, and Monday was Curia’s as the CDMO got its paws on a new drug manufacturing platform. Curia has enlisted enzymatic DNA production outfit Touchlight to furnish its clients with ...

Ara Hacobian Ph.D. Head of Molecular Biology Ludwig Boltzmann Institute for Experimental and Clinical Traumatology David Hercher Ph.D. Master of Science Ludwig Boltzmann Institute for Experimental and ...